Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Dr. Reddy's Laboratories ...

    NYSE: RDY · Real-Time Price · USD
    15.08
    0.21 (1.38%)
    At close: Jul 03, 2025, 1:04 PM
    15.08
    0.00%
    After-hours: Jul 03, 2025, 01:04 PM EDT
    1.38%
    Bid 14.75
    Market Cap 12.55B
    Revenue (ttm) 325.54B
    Net Income (ttm) 56.54B
    EPS (ttm) 0.78
    PE Ratio (ttm) 19.33
    Forward PE 0.22
    Analyst Strong Buy
    Ask 15.25
    Volume 581,921
    Avg. Volume (20D) 1,989,163
    Open 15.08
    Previous Close 14.88
    Day's Range 15.04 - 15.16
    52-Week Range 12.26 - 16.89
    Beta 0.39

    About RDY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RDY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for RDY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 weeks ago
    +5.29%
    Dr. Reddy's Laboratories shares are trading higher... Unlock content with Pro Subscription
    1 month ago
    +3.96%
    Dr. Reddy's Laboratories shares are trading hgher on possible continued strength after reporting better-than-expected Q4 financial results on Friday.
    news image

    4 weeks ago · zacks.com

    RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

    Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

    news image

    4 weeks ago · businesswire.com

    Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

    HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

    news image

    1 month ago · seekingalpha.com

    Dr. Reddy's Continues To Be A Good Buy At Current Valuation

    I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY r...

    news image

    1 month ago · zacks.com

    RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

    Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

    1 month ago · youtube.com

    Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

    Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans ...

    news image

    1 month ago · seekingalpha.com

    Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript

    Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CF...

    news image

    1 month ago · businesswire.com

    Dr. Reddy's Q4 & Full Year FY25 Financial Results

    HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

    Add to Watchlist